Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Sarcoma 6Neoplasms 3Neoplasm Metastasis 2Lymphoma 1Leiomyosarcoma 1

Interventions

pembrolizumab 58Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 25Irinotecan 24Carboplatin 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × olaratumab × Clear all
NCT02677116 2020-05-20

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Eli Lilly and Company

Phase 1 Completed
68 enrolled 26 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01199822 2017-04-14

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Completed
16 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡